Canadian Network for Mood and Anxiety Treatments (CANMAT) consensus recommendations for functional outcomes in major depressive disorder

Raymond W. Lam, Sagar V. Parikh, Erin E. Michalak, Carolyn S Dewa, Sidney H. Kennedy

Research output: Contribution to journalReview article

23 Citations (Scopus)

Abstract

BACKGROUND: Functional recovery is increasingly recognized as a priority in the treatment of major depressive disorder (MDD), by both clinicians and patients. However, symptom improvement remains the focus of traditional clinical trials for MDD and of the regulatory approval process for new medications and other interventions. Many studies have shown that functional outcomes do not always correspond to symptom-based outcomes. METHODS: Representatives from clinical practice, professional societies, academia, industry, and government were invited by the Canadian Network for Mood and Anxiety Treatments to develop recommendations for the conceptualization and measurement of functional outcomes in clinical trials of MDD. RESULTS: Definitions and conceptual frameworks to guide assessment of functioning are described, as well as research methodology applicable to the broad spectrum of treatments for MDD. Examples are given for validated instruments, including patient-reported outcome measures. Strategies for knowledge translation and dissemination are suggested and consensus recommendations summarized. CONCLUSIONS: As the societal burden and financial costs of MDD continue to escalate, so does the need for evidence-based and cost-effective interventions that demonstrate improvement in functioning. Routine assessment of functional outcomes will benefit not only individuals with MDD but also diverse stakeholders concerned about the efficacy and cost-effectiveness of interventions.

Original languageEnglish (US)
Pages (from-to)142-149
Number of pages8
JournalAnnals of Clinical Psychiatry
Volume27
Issue number2
StatePublished - May 1 2015
Externally publishedYes

Fingerprint

Major Depressive Disorder
Consensus
Anxiety
Therapeutics
Clinical Trials
Costs and Cost Analysis
Professional Practice
Translational Medical Research
Cost-Benefit Analysis
Industry
Research Design
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Medicine(all)

Cite this

Canadian Network for Mood and Anxiety Treatments (CANMAT) consensus recommendations for functional outcomes in major depressive disorder. / Lam, Raymond W.; Parikh, Sagar V.; Michalak, Erin E.; Dewa, Carolyn S; Kennedy, Sidney H.

In: Annals of Clinical Psychiatry, Vol. 27, No. 2, 01.05.2015, p. 142-149.

Research output: Contribution to journalReview article

@article{9b5a2553b8e644beb91e725d82f78aac,
title = "Canadian Network for Mood and Anxiety Treatments (CANMAT) consensus recommendations for functional outcomes in major depressive disorder",
abstract = "BACKGROUND: Functional recovery is increasingly recognized as a priority in the treatment of major depressive disorder (MDD), by both clinicians and patients. However, symptom improvement remains the focus of traditional clinical trials for MDD and of the regulatory approval process for new medications and other interventions. Many studies have shown that functional outcomes do not always correspond to symptom-based outcomes. METHODS: Representatives from clinical practice, professional societies, academia, industry, and government were invited by the Canadian Network for Mood and Anxiety Treatments to develop recommendations for the conceptualization and measurement of functional outcomes in clinical trials of MDD. RESULTS: Definitions and conceptual frameworks to guide assessment of functioning are described, as well as research methodology applicable to the broad spectrum of treatments for MDD. Examples are given for validated instruments, including patient-reported outcome measures. Strategies for knowledge translation and dissemination are suggested and consensus recommendations summarized. CONCLUSIONS: As the societal burden and financial costs of MDD continue to escalate, so does the need for evidence-based and cost-effective interventions that demonstrate improvement in functioning. Routine assessment of functional outcomes will benefit not only individuals with MDD but also diverse stakeholders concerned about the efficacy and cost-effectiveness of interventions.",
author = "Lam, {Raymond W.} and Parikh, {Sagar V.} and Michalak, {Erin E.} and Dewa, {Carolyn S} and Kennedy, {Sidney H.}",
year = "2015",
month = "5",
day = "1",
language = "English (US)",
volume = "27",
pages = "142--149",
journal = "Annals of Clinical Psychiatry",
issn = "1040-1237",
publisher = "Dowden Health Media,Inc",
number = "2",

}

TY - JOUR

T1 - Canadian Network for Mood and Anxiety Treatments (CANMAT) consensus recommendations for functional outcomes in major depressive disorder

AU - Lam, Raymond W.

AU - Parikh, Sagar V.

AU - Michalak, Erin E.

AU - Dewa, Carolyn S

AU - Kennedy, Sidney H.

PY - 2015/5/1

Y1 - 2015/5/1

N2 - BACKGROUND: Functional recovery is increasingly recognized as a priority in the treatment of major depressive disorder (MDD), by both clinicians and patients. However, symptom improvement remains the focus of traditional clinical trials for MDD and of the regulatory approval process for new medications and other interventions. Many studies have shown that functional outcomes do not always correspond to symptom-based outcomes. METHODS: Representatives from clinical practice, professional societies, academia, industry, and government were invited by the Canadian Network for Mood and Anxiety Treatments to develop recommendations for the conceptualization and measurement of functional outcomes in clinical trials of MDD. RESULTS: Definitions and conceptual frameworks to guide assessment of functioning are described, as well as research methodology applicable to the broad spectrum of treatments for MDD. Examples are given for validated instruments, including patient-reported outcome measures. Strategies for knowledge translation and dissemination are suggested and consensus recommendations summarized. CONCLUSIONS: As the societal burden and financial costs of MDD continue to escalate, so does the need for evidence-based and cost-effective interventions that demonstrate improvement in functioning. Routine assessment of functional outcomes will benefit not only individuals with MDD but also diverse stakeholders concerned about the efficacy and cost-effectiveness of interventions.

AB - BACKGROUND: Functional recovery is increasingly recognized as a priority in the treatment of major depressive disorder (MDD), by both clinicians and patients. However, symptom improvement remains the focus of traditional clinical trials for MDD and of the regulatory approval process for new medications and other interventions. Many studies have shown that functional outcomes do not always correspond to symptom-based outcomes. METHODS: Representatives from clinical practice, professional societies, academia, industry, and government were invited by the Canadian Network for Mood and Anxiety Treatments to develop recommendations for the conceptualization and measurement of functional outcomes in clinical trials of MDD. RESULTS: Definitions and conceptual frameworks to guide assessment of functioning are described, as well as research methodology applicable to the broad spectrum of treatments for MDD. Examples are given for validated instruments, including patient-reported outcome measures. Strategies for knowledge translation and dissemination are suggested and consensus recommendations summarized. CONCLUSIONS: As the societal burden and financial costs of MDD continue to escalate, so does the need for evidence-based and cost-effective interventions that demonstrate improvement in functioning. Routine assessment of functional outcomes will benefit not only individuals with MDD but also diverse stakeholders concerned about the efficacy and cost-effectiveness of interventions.

UR - http://www.scopus.com/inward/record.url?scp=84947056200&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947056200&partnerID=8YFLogxK

M3 - Review article

C2 - 25954941

AN - SCOPUS:84947056200

VL - 27

SP - 142

EP - 149

JO - Annals of Clinical Psychiatry

JF - Annals of Clinical Psychiatry

SN - 1040-1237

IS - 2

ER -